Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis (SSc).
Authors of a meta-analysis aimed to systematically assess the safety and efficacy profile of rituximab in patients with systemic sclerosis.
Study authors conducted a systematic review and meta-analysis on the incidence and prevalence of systemic sclerosis.
Researchers assessed the safety and efficacy of B-cell depletion for systemic sclerosis-associated pulmonary arterial hypertension.
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
The researchers conducted an extensive pain assessment of patients with systemic sclerosis, examining pain chronification and its association with disease manifestations.
A team of investigators sought to determine the prevalence of proton pump inhibitor-partial response gastroesophageal reflux disease in patients with systemic sclerosis.
The FDA has granted Orphan Drug designation to TMB-003 (Timber Pharmaceuticals) for the treatment of systemic sclerosis.
Researchers evaluated obstetric complications in women with a systemic sclerosis diagnosis vs the general obstetric population.
The performance of 5 core set measure in ACR-CRISS in recent trials was explored, and their ability to discern the active medication group from placebo in patients with diffuse cutaneous systemic sclerosis (dcSSc), was assessed.